This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Avi Kapoor 17 hours ago
MarketsTrading IdeasPre-Market OutlookNewsAnalyst RatingsDowngrades
Analysts downgraded BAER, NYT, CRK, PODD and SMMT, lowering price targets for four and adopting more cautious outlooks.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Canaccord Genuity analyst Austin Moeller downgraded Bridger Aerospace Group Holdings, Inc. (NASDAQ:BAER) from Buy to Hold and lowered the price target from $4 to $1. Bridger Aerospace closed at $0.19 on Tuesday. See how other analysts view this stock.
- Citigroup analyst Jason Bazinet downgraded The New York Times Company (NYSE:NYT) from Buy to Neutral and cut the price target from $85 to $76. New York Times shares closed at $73.82 on Tuesday. See how other analysts view this stock.
- Morgan Stanley analyst Devin McDermott downgraded Comstock Resources, Inc. (NYSE:CRK) from Equal-Weight to Underweight and maintained the price target of $13. Comstock Resources closed at $14.39 on Tuesday. See how other analysts view this stock.
- Stifel analyst Jonathan Block downgraded Insulet Corporation (NASDAQ:PODD) from Buy to Hold and slashed the price target from $180 to $165. Insulet shares closed at $145.34 on Tuesday. See how other analysts view this stock.
- Bernstein analyst Jeffrey Walch downgraded Summit Therapeutics Inc. (NASDAQ:SMMT) from Market Perform to Underperform and lowered the price target from $11.9 to $8.3. Summit Therapeutics closed at $10.67 on Tuesday. See how other analysts view this stock.
Considering buying PODD stock? Here’s what analysts think:

Photo via Shutterstock
